8/14/2019 7:05:49 AM
AC Immune Q2 Net Loss CHF 16.9 Mln Vs Loss CHF 11.1 Mln Last Year
7/17/2019 7:08:53 AM
AC Immune Initiates Phase 1 Study Of ACI-3024 Small Molecule Tau Morphomer For Alzheimer’s Disease
6/28/2019 8:41:38 AM
AC Immune Shareholders Elect Douglas Williams As Chairman Of Board At AGM
6/20/2019 7:11:15 AM
AC Immune Begins Phase 2 Substudy To Increase Understanding Of Disease Progression In Familial Alzheimer’s Disease
6/20/2019 7:06:16 AM
AC Immune: Genentech Begins Substudy In Ongoing Phase 2 API Trial
2/20/2019 7:12:18 AM
AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial In Moderate Alzheimer’s Disease
1/3/2019 4:01:08 AM
AC Immune Appoints Marie Kosco-Vilbois As Chief Scientific Officer
12/19/2018 7:15:10 AM
WuXi Biologics And AC Immune To Establish Strategic Partnership
12/19/2018 6:40:45 AM
AC Immune, WuXi Biologics Announce First Steps Of Exclusive Strategic Collaboration
12/12/2018 6:01:04 AM
Lilly, AC Immune Announce License And Collaboration Agreement
11/9/2018 4:02:24 AM
AC Immune Shares Insights From Key Opinion Leader Meeting On Abeta Oligomers In AD And Other Misfolded Proteins
10/22/2018 4:04:08 AM
AC Immune Announces Andreas Muhs, Chief Scientific Officer, To Take Medical Leave Of Absence
8/20/2018 4:02:51 AM
AC Immune Announces Important Clinical Milestones For ACI-24 Vaccine In Alzheimer's Disease And Down Syndrome
7/17/2018 4:14:31 AM
AC Immune Says Crenezumab's Second Phase 3 Trial (CREAD 2) Fully Recruited